HIV regulatory proteins: potential targets for therapeutic intervention.
With the incidence of HIV infection on the rise worldwide, it is obvious that new approaches must be taken to halt the spread of disease. Unfortunately, this is no easy task; of all retroviruses studied to date HIV remains the most complex in terms of genomic organization, regulation of gene expression, and replication. However, as the mechanism of action of the unique viral regulatory proteins is deciphered, new windows of opportunity for attacking the virus like cycle are opened. The essential regulatory function served by both Tat and Rev transacting regulatory proteins makes them attractive targets for prophylactic and therapeutic intervention. This review will focus on our current understanding of Tat and Rev function.
Rosen
C A
CA
Department of Gene Regulation, Roche Institute of Molecular Biology, Nutley, NJ 07110-1199.
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D001483:Base Sequence; D005544:Forecasting; D015694:Gene Products, rev / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015696:Gene Products, tat / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008969:Molecular Sequence Data; D012367:RNA, Viral / Q000378:metabolism; D054321:rev Gene Products, Human Immunodeficiency Virus; D054322:tat Gene Products, Human Immunodeficiency Virus
D000998:Antiviral Agents; D015694:Gene Products, rev; D015696:Gene Products, tat; D012367:RNA, Viral; D054321:rev Gene Products, Human Immunodeficiency Virus; D054322:tat Gene Products, Human Immunodeficiency Virus